Menu

David Peinsipp

Partner

I believe corporate law can be as creative and disruptive as the clients I represent.

dpeinsipp@cooley.com

David is co-chair of Cooley's global capital markets practice group. David practices general business and corporate law, representing both emerging and public companies in a variety of matters, including capital markets transactions, Securities and Exchange Commission (SEC) reporting and compliance and corporate governance matters. He routinely represents issuers and investment banks in complex securities offerings, including IPOs, follow-on offerings, 144A offerings, PIPEs, deSPACs and direct listings. His practice also includes company formations, venture financings and general corporate matters.

Download full bio 

Experience

  • LumiraDx Limited – $100.3 Million Follow-on Offering and Concurrent Private Placement 

  • Pliant Therapeutics – $230.0 Million Follow-on Offering 

  • Arcutis Biotherapeutics – $172.5 Million Follow-on Offering 

  • Zymeworks – $115 Million Follow-On Offering 

  • Grindr Agrees to Merge With SPAC Tiga Acquisition Corp. 

  • View all

Education

  • New York University School of Law
    JD, 2001

  • University of Florida
    BS, Psychology
    1998


Admissions & Credentials

California

Memberships

  • American Bar Association

  • The Bar Association of San Francisco

Rankings & Accolades

    Daily Journal: California Lawyer Attorneys of the Year Awards (2020); Top 100 Lawyers in California (2019 – 2020); Top 20 Under 40 (2014)

    Chambers USA: Capital Markets: Debt & Equity – California & Nationwide (Western United States) (2019 – 2022)

    IFLR1000 US: Lawyer of the Year – Capital Markets (2020)

    Law 360: Capital Markets MVP (2019)

    Legal 500: Leading Lawyer - Capital Markets: Equity Offerings (2020 – 2022); Next Generation Lawyer - Capital Markets: Equity (2019)

Representative issuers:

Dave has represented companies/investment banks on capital market transactions involving issuers across industries, such as: 10X Genomics, 4D Molecular Therapeutics, Accelerate Diagnostics, Acutus Medical, Aerohive Networks, Alteryx, ALX Oncology, Ambarella, Amyris, Applied Molecular Transport, Anthera Pharmaceuticals, Apigee, Applied Molecular Transport, Annexon, Apptio, Arcadia Biosciences, Arcutis Biotherapeutics, Aridis Pharmaceuticals, ARMO BioSciences, Ascendis Pharma, ASLAN Pharmaceuticals, Atlassian, Athira Pharma, Audentes Therapeutics, Cision, Crinetics Pharmaceuticals, Dermira, DocuSign, Doximity, Dutch Bros., EHang, Eidos Therapeutics, Expensify, Fantex, FIGS, FireEye, Five Prime Therapeutics, Global Blood Therapeutics, Gossamer Bio, Graphite Bio, Gritstone Oncology, Guardant Health, Health Catalyst, HealthEquity, Hyperion Therapeutics, IGM Biosciences, Ignyta, Immune Design, Inhibrx, Invitae, Kinnate Biopharma, Kodiak Sciences, LinkedIn, Livongo Health, Lulu’s Fashion Lounge, Lyell Immunopharma, MINDBODY, Mobile Iron, NantKwest, Nanthealth, NerdWallet, New Relic, Olema Pharmaceuticals, Ooma, Opendoor Labs, Otonomy, Pliant Therapeutics, Principia Biopharma, PROCEPT BioRobotics, ProNai, ProQR Therapeutics, PROS Holdings, Rigel Pharmaceuticals, Qualtrics, Root, Sana Biotechnology, Satsuma Pharmaceuticals, Savara, Shockwave Medical, Sierra Oncology, Smart Share Global, Snap, Stitch Fix, Sutro Biopharma, Sweetgreen, Syndax Pharmaceuticals, Tableau Software, Taiwan Liposome Company, Treace Medical Concepts, Tricida, Trivascular, Twilio, Uber, Ventyx, ViewRay, Warby Parker, Wish, Xenon Pharmaceuticals, Xometry, Yelp, Zendesk, Zscaler, Zymeworks, Zynga.